Digital Darwinism is when technology and society evolve faster than an organization can adapt. Digital Darwinism is a fate that threatens most organizations in almost every industry, but particularly in the pharmaceutical industry in India.Read More Digital Darwinism
Initial reactions of the stock market to Donald Trump’s victory in the US Presidential Elections is one of joy as witnessed by the jump in share prices. This is obviously a very unmuted reaction to the settling down of the anti-pharma rhetoric offered by Hillary Clinton. While investor sentiment is obvious, what I find surprising […]Read More Donald J. Trump is POTUS
We live in exciting times. New technology and innovation that can change the way we live, is pouring out at unprecedented frequency. It is well known that although the pharmaceutical industry is considered to be very technologically advanced, it is also one that is quite inward focused and therefore stuck in the past. Therefore, it […]Read More Current and Future Trends for Pharma
For the Indian pharmaceutical industry, ‘challenge’ has come to be its middle name. While for one part of the industry it is to create newer and better medicines for the diseases of tomorrow, for the rest of it; the challenge is simply to get to that tomorrow. 40 years after India aspired for self-sufficiency in […]Read More “Challenge” – Pharma’s middle name
Of late, the pharmaceutical industry has been in the news for all the wrong reasons. First, the government intervened to bring in large groups of medicines under the price cap to make them more affordable to the sick. Even before that happened, companies were caught overcharging for some medicines in violation of the prices set […]Read More India Pharma – Of Markets and Morals
The post-9/11 world was a difficult place for both political and business leaders to adjust to. As power structures in the world shifted, the developed world struggled to retain political and economic control in a scenario sometimes described as the ‘decline of the West’. Capital fled these risky markets in search of those that were […]Read More Will pharma forsake emerging markets?
Rapid change across the pharmaceutical industry in India is causing many companies to re-evaluate their sales and marketing strategies. The rampant generic nature of the market leaves it commoditized with little to no leg-room for branding and differentiation. The threat of price control and loose IP laws discourage the launch of innovative products leaving little […]Read More A pinch of creativity and a fist full of commercial effectiveness
When discussing why the pharmaceutical industry does not use social media, Andrew Spong (@andrewspong), one of the best known names on the health care social media circuit once tweeted, “Without the change in mindset, for pharma SM can be akin to trying to hold a conversation through the sealed doors of a blast shelter” […]Read More Sealed Doors of Bomb Shelters
Successful innovation is seen as one of the most important means through which the global pharmaceutical industry competes and grows, especially in the current era of the knowledge economy. Since its inception, the industry has always aimed to achieve innovation led growth. This is because a direct causal link is often assumed between innovation and […]Read More Impact of declining R&D on innovation
Republished with the kind permission of http://www.pharmaphorum.com – follow @pharmaphorum on Twitter for the latest articles During his visit to India in late 2010, US President Barack Obama surprised many when he remarked to the Indian Parliament that he thought of India as not simply an emerging market but as one that has already emerged. […]Read More India – Established or Emerging Health care Market?